{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:01Z","timestamp":1787026621341,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ravulizumab is a long-acting C5 complement inhibitor that provides sustained suppression of the complement pathway. It is currently approved by the US Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome. With its increasing clinical use, concerns regarding Ravulizumab-associated adverse drug reactions have grown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study utilized a dataset extracted from the Adverse Event Reporting System (FAERS) database, comprising adverse event reports from the fourth quarter of 2018 to the second quarter of 2025. Four distinct disproportionality analysis methods\u2014the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN)\u2014were applied. Additionally, the time-to-onset profile of adverse events was assessed using the Weibull distribution model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 9,090 adverse event reports associated with ravulizumab were included in this analysis. Commonly reported adverse events included fatigue, asthenia, headache, malaise, dyspnea, back pain, feeling abnormal, and diplopia. Furthermore, potential adverse events not listed on the drug label were identified, such as anemia, dysphagia, urinary tract infection, and somnolence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This investigation identified several adverse events associated with ravulizumab and revealed potential adverse reaction signals that were not previously recognized. Healthcare providers may consider these safety signals to more comprehensively assess potential risks in patients during clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1736692","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:03:43Z","timestamp":1772003023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyou","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100739","article-title":"The role of complement in the pathogenesis and treatment of myasthenia gravis","volume":"14","author":"Martinez Salazar","year":"2025","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(03)00111-1","article-title":"Complement therapeutics: history and current progress","volume":"40","author":"Morgan","year":"2003","journal-title":"Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1568010043483890","article-title":"The possibilities and pitfalls for anti-complement therapies in inflammatory diseases","volume":"3","author":"Mizuno","year":"2004","journal-title":"Curr Drug Targets Inflammation Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02235-4","article-title":"Pharmacological therapies in paroxysmal nocturnal haemoglobinuria: focus on complement inhibition","volume":"85","author":"Kelly","year":"2025","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.125","article-title":"The complement system as a potential therapeutic target in rheumatic disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015777","article-title":"Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy","volume":"9","author":"Padilla Kelley","year":"2025","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina","year":"2019","journal-title":"Ther Apher Dial"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med"},{"key":"B16","volume-title":"Signal Analysis in Pharmacovigilance Principles and Processes","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.v13:8","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ane.v146.5","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: A disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.v10:6","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106311","article-title":"Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders","volume":"95","author":"Vieira","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1634\/theoncologist","article-title":"FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00210-1","article-title":"Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial","volume":"9","author":"de Latour","year":"2022","journal-title":"Lancet Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03630-x","article-title":"Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan","volume":"118","author":"Nishimura","year":"2023","journal-title":"Int J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria","volume":"21","author":"Kelly","year":"2024","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667249","article-title":"Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e70158","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur J Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:03:44Z","timestamp":1772003024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1736692"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1736692","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1736692"}}